IMP1734

IMP1734 · Eikon Therapeutics

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMP1734, covering 2026-03-23 to 2026-03-23. Get the full timeline:

Most recent: Clinical Trial Update: A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors [Phase 1, Phase 2]

See pricing